protein kinase C and casein kinase substrate in neurons 3Genealiases: CMYO27 · SDPIII
Q-omics provides the consensus-scored PACSIN3 profile across patient tissues and cancer cell-line models. PACSIN3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PACSIN3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PACSIN3 protein abundance shows 18,779 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, KIRC, and HNSC as cancer lineages where PACSIN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PACSIN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PACSIN3 survival associations across molecular data types. PACSIN3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PACSIN3 RNA expression–survival associations across cancer types. High PACSIN3 expression shows unfavorable associations in LGG and PAAD, but favorable associations in UVM, UCS, OV and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for PACSIN3 RNA expression.
This table summarizes PACSIN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PACSIN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PACSIN3 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUSC, COAD, BLCA and BRCA. The KIRC box plot shows higher PACSIN3 RNA expression in normal versus tumor tissue (log2 FC = −0.658, t-test p < 0.001).
This table shows molecular features associated with PACSIN3 in patient tissues and cancer cell lines. In patient samples, PACSIN3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PACSIN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
